Foundation for Innovative New Diagnostics

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022 Signed FIND R&D collaboration contract extension Entered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S. Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc. Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022. Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to the company’s revenue of approximately $1.44 million in the first half of 2022. Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022. Total operating expenses decreased by approximately 6% in the first half of 2023 to approximately $11.9 million compared to approximately $12.6 million for the same period in 2022. Cash and cash equivalents were approximately $3.2 million as of June 30, 2023, compared with approximately $7.4 million as of December 31, 2022. As previously reported, and in light of the Company’s business performance and current cash position, the Company does not expect that its current cash will be sufficient to fund operations beyond September 2023. Since the end of the second quarter, the Company has pursued options to improve its cash position or mitigate a liquidity shortfall. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company continues to consider all alternatives, including restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying the Company’s business activities, selling assets, and other strategic transactions or other measures, including obtaining relief under U.S. as well as applicable foreign bankruptcy laws. There is no guarantee that the Company will be able to identify and execute on any of these alternatives or that any of them will be successful. In the reporting quarter and year to date, the Company reached the following key milestones: OpGen subsidiary, Curetis, and FIND signed an extension to their R&D collaboration agreement for the development of an AMR panel on the Unyvero A30 RQ platform for low- and middle-income countries. This next phase covers full development of AMR assay and cartridge, analytical testing and software development. Curetis successfully completed the first phase of its FIND collaboration, including the expanded scope of the FIND project in Q1 and Q2, respectively. The FIND collaboration contributed $609 thousand to first half 2023 revenue. In June 2023, OpGen received ten Unyvero A30 C-Series instruments which will be used in the next phase of the FIND collaboration. Curetis announced the completion of two interim milestones of its collaboration project with InfectoGnostics under the PREPLEX grant. The Company submitted a De Novo classification request to the FDA for marketing authorization of the Unyvero Urinary Tract Infection (UTI) panel. Following the FDA’s substantive review of the Company’s submission, the Company received a formal communication from the FDA requesting certain additional information on June 30, 2023. The FDA has provided OpGen with 180 days to fully respond to their requests. OpGen entered into a distribution agreement with Fisher Healthcare, a division of Thermo Fisher Scientific, for the distribution of the Unyvero A50 platform and in vitro diagnostic tests for pneumonia and urinary tract infections in the U.S. During the second quarter and year-to-date, the Company successfully completed vendor set-up of OpGen under Fisher Healthcare’s systems, trained the Fisher Healthcare sales teams across the U.S., created digital marketing campaigns, and identified several hundred potential high priority leads with the Fisher Healthcare team. In several territories, the teams are already working towards commercial customer contract opportunities. With the assistance of a U.S.-Chinese strategic advisory firm, OpGen continues to have an active strategic corporate business development campaign to over 40 Chinese corporate IVD companies potentially interested in the Unyvero A30 RQ. Following a successful feasibility assessment, the Ares team recently signed an annual genomic surveillance contract with a major U.S. healthcare network to sequence and analyze pathogen isolates on a twice weekly basis. In addition, the team has signed multiple new ARESiss contracts for isolate sequencing and new AREScloud subscriptions for web-based sequence analysis. On the IP front, OpGen’s subsidiary, Ares Genetics, successfully defended a key patent that was being contested in Europe. In the ruling, the European Patent Office ruled in favor of maintaining the patent, which broadly covers the prediction of AMR in pathogens based on any genetic determinants involving two or more nucleotides. Ares recently announced a new feature release for its AREScloud software designed to enhance genomic surveillance. These features include a Single Nucleotide Polymorphism (SNP) analysis module and interpretation of plasmids with reporting customized for the needs of hospital epidemiologists. Conference Call Information OpGen’s management will host a conference call today, August 10, 2023 at 4:30 p.m. ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions. Conference Call Details U.S. Dial-in Number: 1-877-704-4453 International Dial-in Number: 1-201-389-0920 Webcast: Following the conclusion of the conference call, a replay will be available through August 24, 2023. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at . A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings. Replay Details U.S. Dial-in Number: 1-844-512-2921 International Dial-in Number: 1-412-317-6671 Replay PIN: 13739109 About OpGen, Inc. OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud. For more information, please visit Forward-Looking Statements This press release includes statements regarding the second quarter 2023 and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to continue to finance our business and operations, the result of any alternatives to mitigate the Company’s cash position, including restructuring or refinancing of our debt, seeking additional debt or equity capital, reducing or delaying our business activities, selling assets, other strategic transactions or other measures, including obtaining relief under U.S. bankruptcy laws, and the terms, value and timing of any transaction resulting from such alternatives, our ability to satisfy debt obligations under our loan with the European Investment Bank, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. OpGen: Oliver Schacht President and CEO InvestorRelations@opgen.com OpGen Investor & Press Contact: Alyssa Factor Edison Group afactor@edisongroup.com OpGen, Inc. Consolidated Balance Sheets (unaudited) June 30, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents $ 3,237,176 $ 7,440,030 Accounts receivable, net 619,575 514,372 Inventory, net 1,735,122 1,345,137 Prepaid expenses and other current assets 1,637,593 1,355,949 Total current assets 7,229,466 10,655,488 Property and equipment, net 3,849,734 3,457,531 Finance lease right-of-use assets, net 1,833 3,500 Operating lease right-of-use assets 2,041,010 1,459,413 Intangible assets, net 7,206,382 7,440,974 Strategic inventory 1,609,643 2,300,614 Other noncurrent assets 496,894 495,629 Total assets $ 22,434,962 $ 25,813,149 Liabilities and Stockholders’ Equity Current liabilities Current maturities of long-term debt $ 9,191,151 $ 7,023,901 Accounts payable 195,253 420,821 Accrued compensation and benefits 1,439,181 1,097,654 Accrued liabilities 1,043,123 1,526,204 Deferred revenue 27,279 142,061 Short-term finance lease liabilities 1,962 3,364 Short-term operating lease liabilities 517,602 377,626 Total current liabilities 12,415,551 10,591,631 Long-term debt, net — 4,850,686 Derivative liabilities 45,656 99,498 Long-term finance lease liabilities — 280 Long-term operating lease liabilities 2,987,194 2,566,138 Other long-term liabilities 126,671 129,368 Total liabilities 15,575,072 18,237,601 Stockholders' equity Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2023 and December 31, 2022, respectively — — Common stock, $0.01 par value; 100,000,000 shares authorized; 6,967,699 and 2,899,911 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 69,677 28,999 Additional paid-in capital 291,935,388 281,167,161 Accumulated deficit (284,388,698 ) (272,824,772 ) Accumulated other comprehensive loss (756,477 ) (795,840 ) Total stockholders’ equity 6,859,890 7,575,548 Total liabilities and stockholders’ equity $ 22,434,962 $ 25,813,149 OpGen, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue Product sales $ 439,672 $ 889,271 $ 850,569 $ 1,255,323 Laboratory services 44,003 20,570 65,676 63,499 Collaboration revenue 252,462 57,364 733,336 118,128 Total revenue 736,137 967,205 1,649,581 1,436,950 Operating expenses Cost of products sold 714,392 646,389 1,306,770 938,386 Cost of services 204,102 15,650 332,408 46,212 Research and development 1,388,792 2,273,756 3,201,624 4,590,197 General and administrative 2,425,007 2,134,266 4,848,960 4,759,319 Sales and marketing 1,160,200 1,169,349 2,186,287 2,220,781 Total operating expenses 5,892,493 6,239,410 11,876,049 12,554,895 Operating loss (5,156,356 ) (5,272,205 ) (10,226,468 ) (11,117,945 ) Other (expense) income Interest and other income 31,215 13,851 61,323 16,972 Interest expense (684,498 ) (779,912 ) (1,301,796 ) (2,049,493 ) Foreign currency transaction (losses) gains (60,401 ) 271,967 (152,396 ) 470,707 Change in fair value of derivative financial instruments 42,717 (74,116 ) 55,411 35,628 Total other expense (670,967 ) (568,210 ) (1,337,458 ) (1,526,186 ) Loss before income taxes (5,827,323 ) (5,840,415 ) (11,563,926 ) (12,644,131 ) Provision for income taxes — — — — Net loss $ (5,827,323 ) $ (5,840,415 ) $ (11,563,926 ) $ (12,644,131 ) Net loss available to common stockholders $ (5,827,323 ) $ (5,840,415 ) $ (11,563,926 ) $ (12,644,131 ) Net loss per common share - basic and diluted $ (0.93 ) $ (2.51 ) $ (2.13 ) $ (5.43 ) Weighted average shares outstanding - basic and diluted 6,246,326 2,328,725 5,424,542 2,326,485 Net loss $ (5,827,323 ) $ (5,840,415 ) $ (11,563,926 ) $ (12,644,131 ) Other comprehensive (loss) income - foreign currency translation (113,704 ) (1,227,142 ) 39,363 (1,710,991 ) Comprehensive loss $ (5,941,027 ) $ (7,067,557 ) $ (11,524,563 ) $ (14,355,122 )

Preliminary Total Revenue for Q3 2022 was approximately $0.4 million Cash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 million Additional customer contract for Acuitas AMR Gene Panel signed in Q3 2022 ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the third quarter of 2022 was approximately $0.4 million, down from $1.2 million in the third quarter of 2021. Cash as of September 30, 2022 was approximately $10.3 million and, following the successful closing of a financing transaction, was approximately $13.3 million as of October 3, 2022. The company announced accomplishment of the following key milestones and recent developments in the third quarter of 2022: OpGen subsidiary Curetis and BioVersys signed a collaboration agreement for clinical trial support OpGen signed another commercial customer contract for the Acuitas AMR Gene Panel OpGen closed a registered direct offering for gross proceeds of $3.38 million on October 3, 2022 OpGen announced successful completion of clinical trial enrollment for the Unyvero Urinary Tract Infection Panel OpGen subsidiary Curetis and FIND signed a R&D collaboration agreement for the Unyvero A30 RQ platform Nasdaq granted OpGen a 180-day extension to meet Nasdaq’s minimum bid price requirement OpGen launched ARES sequencing services in the U.S. from its Rockville, Maryland laboratory OpGen subsidiary Ares Genetics GmbH entered into a collaboration agreement with the Belgian national reference center for invasive S. pneumoniae at University Hospital Leuven Mr. Schacht commented, “We have seen a decrease in revenue in Q3 2022 compared to last year’s third quarter due to the completion of the New York State Department of Health project in Q3 last year, and lower than expected ARES sales. Our preliminary quarterly results do not reflect the potential impact from the FIND collaboration agreement, which is expected to culminate with a series of milestones and deliverables at the end of Q1 2023. Acuitas sales are not reflected in the third quarter numbers at a material level either, since the first couple of sites became operational with completed systems installations and trainings in October. We have been informed by Beijing Clear Biotech’s regulatory advisors about NMPA feedback regarding our Unyvero A50 pneumonia product which would require us to re-submit in China under a new electronic filing regime. We are in dialog with them to gain further insights and assess the potential impact on the overall process and timelines and will provide an update as soon as practicable.” The preliminary Q3 2022 financial results are estimates prior to the completion of OpGen’s financial closing procedures and review procedures by its external auditors and therefore may be subject to adjustment when the actual results are available. About OpGen, Inc. OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit. For more information, please visit . Forward-Looking Statements This press release includes statements regarding OpGen’s third quarter 2022 results and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. OpGen: Oliver Schacht President and CEO InvestorRelations@opgen.com OpGen Press Contact: Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.com OpGen Investor Contact: Alyssa Factor Edison Group afactor@edisongroup.com

FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs)Initial project focuses on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers from blood cultureFeasibility phase of R&D project set to conclude by the end of Q1-2023 and co-funded by FIND with euro 700,000 ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing from blood culture samples in low and middle income countries (LMICs). The Unyvero A30 RQ platform is a sample to answer instrument running a disposable one-time use cartridge that can test for up to 33 diagnostic targets from a single specimen. Time to result can be as fast as under 30 minutes for very simple tests and around 45 to 90 minutes for most applications. Given the favorable cost of goods profile of both the instrument as well as the disposable cartridge, this system also lends itself to being deployed in LMICs with constrained resources. During the anticipated feasibility project, OpGen’s R&D team at its German subsidiary Curetis GmbH will strive to develop a molecular test panel providing a comprehensive set of pathogen ID and AMR detection assays, develop an easy to perform workflow being compatible with available blood culture systems in target regions without any need for separate sample preparation steps and to adapt some key features of the A30 RQ platform important for use in environments often found in LMICs, such as those with continuous operation with unstable power grids. Oliver Schacht, President & CEO of OpGen, commented, “We are excited to partner with FIND, in demonstrating that our Unyvero A30 RQ platform is ideally suited to being used in LMICs for rapid detection of AMR which is a truly global issue that must be addressed in a multilateral and indeed global fashion. The R&D contract and associated funding will support the required R&D efforts on our side and expedite such development.” Cecilia Ferreyra, Director of AMR at FIND, said: “AMR is one of the most pressing health emergencies of our time, with the potential to undo decades of medical progress. Simplifying blood culture systems so that the pathogen responsible for an illness and its resistance profile can both be identified quickly is crucial for halting and preventing this silent pandemic, especially in LMICs that bear the greatest burden of AMR.” If successful, after demonstrating feasibility and completing this initial R&D project phase, both parties have agreed to discuss the option of a potential future collaboration and commercialization agreement between OpGen and FIND. Such future collaboration agreement would aim to bring the Unyvero A30 RQ platform and initial application products through required clinical studies and regulatory approvals in LMICs to make them commercially available at an attractive cost profile to commercial distribution partners, which we believe can address this unmet medical need for rapid AMR detection in LMICs. About OpGen, Inc. OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit. For more information, please visit www.opgen.com. Forward-Looking Statements This press release includes statements regarding the R&D collaboration agreement entered into by OpGen’s subsidiary Curetis GmbH and FIND, the global foundation for innovative new diagnostics. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. OpGen:Oliver SchachtPresident and CEOInvestorRelations@opgen.com OpGen Press Contact:Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.com OpGen Investor Contact:Alyssa FactorEdison Groupafactor@edisongroup.com